Karyopharm Therapeutics Stock Price, Forecast & Analysis (NASDAQ:KPTI)

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Karyopharm Therapeutics Inc (NASDAQ:KPTI) posted its quarterly earnings data on Monday, November, 4th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.17. The company had revenue of $13.15 million for the quarter, compared to the consensus estimate of $1.61 million. Karyopharm Therapeutics had a negative return on equity of 187.25% and a negative net margin of 909.24%. View Karyopharm Therapeutics' Earnings History.

Karyopharm Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Karyopharm Therapeutics.

6 Wall Street analysts have issued twelve-month target prices for Karyopharm Therapeutics' shares. Their forecasts range from $5.00 to $36.00. On average, they anticipate Karyopharm Therapeutics' share price to reach $20.50 in the next twelve months. This suggests a possible upside of 31.4% from the stock's current price. View Analyst Price Targets for Karyopharm Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Karyopharm Therapeutics.

Headlines about KPTI stock have trended very negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Karyopharm Therapeutics earned a news impact score of -3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term. View News Stories for Karyopharm Therapeutics.

Karyopharm Therapeutics saw a decline in short interest during the month of October. As of October 31st, there was short interest totalling 10,690,000 shares, a decline of 11.4% from the September 30th total of 12,070,000 shares. Based on an average daily volume of 1,600,000 shares, the days-to-cover ratio is currently 6.7 days. Approximately 19.3% of the shares of the stock are short sold. View Karyopharm Therapeutics' Current Options Chain.

Some companies that are related to Karyopharm Therapeutics include Allakos (ALLK), Blueprint Medicines (BPMC), Nektar Therapeutics (NKTR), BridgeBio Pharma (BBIO), GW Pharmaceuticals PLC- (GWPH), Alkermes (ALKS), FibroGen (FGEN), Evotec (EVTCY), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Global Blood Therapeutics (GBT), Genmab A/S (GMAB), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT) and PTC Therapeutics (PTCT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include Gilead Sciences (GILD), Celgene (CELG), Caladrius Biosciences (CLBS), Exelixis (EXEL), Bristol-Myers Squibb (BMY), GW Pharmaceuticals PLC- (GWPH), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA) and Synergy Pharmaceuticals (SGYP).

Karyopharm Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Emerald Advisers LLC (2.42%), Emerald Mutual Fund Advisers Trust (2.31%), Creative Planning (0.33%), California Public Employees Retirement System (0.29%), Private Capital Advisors Inc. (0.19%) and First Midwest Bank Trust Division (0.08%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Institutional Ownership Trends for Karyopharm Therapeutics.

KPTI stock was sold by a variety of institutional investors in the last quarter, including Private Capital Advisors Inc. and First Midwest Bank Trust Division. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Ltd Chione, Michael Kauffman and Sharon Shacham. View Insider Buying and Selling for Karyopharm Therapeutics.

KPTI stock was purchased by a variety of institutional investors in the last quarter, including Creative Planning, Emerald Mutual Fund Advisers Trust, Tibra Equities Europe Ltd, California Public Employees Retirement System, Emerald Advisers LLC, Commonwealth Equity Services LLC and Tower Research Capital LLC TRC . View Insider Buying and Selling for Karyopharm Therapeutics.

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KPTI stock can currently be purchased for approximately $15.60.

Karyopharm Therapeutics has a market capitalization of $979.52 million and generates $30.34 million in revenue each year. The company earns $-178,410,000.00 in net income (profit) each year or ($3.14) on an earnings per share basis. Karyopharm Therapeutics employs 332 workers across the globe.View Additional Information About Karyopharm Therapeutics.

The official website for Karyopharm Therapeutics is http://www.karyopharm.com/.

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]